This begins with the presentation of tumor antigens by the antigen‐presenting cells (such as DCs in the case of DC‐based vaccines) to naive T cells in the lymph nodes that enables the activation of both helper CD4+ T cells and cytotoxic CD8+ T cells. This evidence concerns the gene CD4 and neoplasm.